PCSK9 inhibitors and methods of use thereof
US8673850B2 · kind B2 · utility
12Cited by
3References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 1, 2009 |
| Grant date | Mar 18, 2014 |
| Priority date | — |
| Expiry date | May 29, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/044
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for identifying a compound for preventing or treating a LDLR-associated disease, a VLDLR-associated disease or an ApoER2-associated disease, said method comprising determining whether: a) a level of expression of Annexin A2 nucleic acid or encoded polypeptide; b) a level of Annexin A2 activity; or c) a combination of a) and b), is increased in the presence of a test compound relative to in the absence of said test compound, wherein said increase is indicative that said test compound can be used for preventing or treating a LDLR-associated disease, a VLDLR-associated disease, an ApoER2-associated disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.